Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review.
Diana Prieto-PeñaPilar BernabeuPaloma VelaFrancisco Javier NarváezJesús C Fernández-LópezMercedes Freire-GonzálezBeatriz González-ÁlvarezRoser Solans-LaquéJosé L Callejas RubioNorberto OrtegoCarlos Fernández-DíazEsteban RubioSalvador García-MorilloMauricio MinguezCristina Fernández-CarballidoEugenio de MiguelSheila MelchorEva SalgadoBeatriz BravoSusana Romero-YusteJuan SalvatierraCristina HidalgoSara ManriqueCarlos Romero-GómezPatricia MoyaNoelia Álvarez-RivasJavier MendizabalFrancisco Ortiz-SanjuánIván Pérez de PedroJosé L Alonso-ValdivielsoLaura Perez-SanchezRosa RoldánNagore Fernandez-LlanioRicardo Gómez de la TorreSilvia SuarezMaría Jesús Montesa CabreraMónica Delgado SánchezJavier LoriceraBelén Atienza-MateoSantos CastañedaMiguel Angel González-GayRicardo Blanco-AlonsoPublished in: Therapeutic advances in musculoskeletal disease (2021)
TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.